Stock listing

gettex:0T20 Traws Pharma, Inc. Aktie

German listing (gettex) of Traws Pharma, Inc. · home listing NASDAQ:TRAW

Follow Traws Pharma, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:TRAW

$0.369 USD -0.034 (-8.4%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:TRAW

Since Jul 6, 2026 -52.5% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$0.362 – $0.414 USDOct 16, 2026
Volume
257,684 sharesOct 16, 2026
Market value
$5.68M USDAt the close on Oct 16, 2026 · price × 15.37M shares outstanding
Traws Pharma, Inc. logo
Ticker
gettex:0T20
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Calls

Replays

  • Traws Pharma (NASDAQ:TRAW) Q4 2025 Earnings Call

    Wed, Apr 15, 2026 · 4:30 PM ET

    Watch Transcript

  • Traws Pharma (NASDAQ:TRAW) Q2 2025 Earnings Call

    Thu, Aug 14, 2025 · 8:30 AM ET

    Watch Transcript

Latest news

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Aug 14, 2026

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

Jun 22, 2026

Traws Pharma Provides Regulatory Update on Influenza Program

Jun 12, 2026

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

May 27, 2026

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

May 15, 2026

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

May 8, 2026

Traws Pharma Announces Up to $60 Million Private Placement Financing

Apr 15, 2026

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Feb 19, 2026

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Jan 26, 2026

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Jan 13, 2026

All Traws Pharma, Inc. news

Decks

Traws Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 73 in all · newest Aug 14, 2026 · oldest 2022
Calls
2 calls with a replay · 2 with a transcript · latest Apr 15, 2026
Decks
14 decks · latest Nov 13, 2025

Where Traws Pharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TRAW · Home listingNASDAQUnited StatesUSD
BOATS:TRAWBOATSUnited StatesUSD
gettex:0T20 · This pagegettexGermanyEUR
Munich:0T20MunichGermanyEUR
Frankfurt:0T20FrankfurtGermanyEUR
Lang & Schwarz:A40PJ7Lang & SchwarzGermanyEUR

Log in to ask 6ix AI your own questions about Traws Pharma, Inc.